The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1151
March 3, 2003
View Complete Issue         Table of Contents 2019 
Peginterferon Alfa-2a (Pegasys) for Chronic Hepatitis C
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Peginterferon Alfa-2a (Pegasys) for Chronic Hepatitis C
March 3, 2003 (Issue: 1151)
The FDA has approved recombinant interferon alfa-2a conjugated to polyethylene glycol (Pegasys - Roche) alone or with oral ribavirin (Copegus - Roche) for treatment of adults with chronic hepatitis C virus (HCV) infections not previously treated with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Peginterferon Alfa-2a (Pegasys) for Chronic Hepatitis C
Article code: 1151b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.